These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Canada's third-largest marijuana stock just reported its latest earnings results. Here's what you should know.
It could be smart to buy these pot stocks following their recent slide.
The impressive ways these under-the-radar tech companies are reinventing big markets make them top stocks for investors to buy now.
Marijuana stock Aurora Cannabis is expanding one of its most important projects to increase its growing capacity
This leading vendor of pot packaging is enjoying rapid growth thanks to marijuana legalization.
This commercial-stage company's success depends heavily on the demand for one drug.
Hunting for big dividend-yielding stocks? These top stocks could be the perfect ones to buy.
The company plans to restate its financials, calling its financial controls into question, but there may be a silver lining.
Is one of these two cannabis companies the best marijuana stock to buy now?
These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.
A new retirement study shows that healthcare costs threaten Medicare recipients.
Buying these fast-growing technology companies could prove profit-friendly.
Worry over growing competition caused investors to sell shares in this leading diabetes management company, but that could be a mistake.
The company's making progress in its goal to make genetic screening for healthcare available to everyone.
This beer, wine, and spirits Goliath is selling noncore wine and spirits brands to double down on its higher-margin beer brands.
A ranking of the top marijuana growers by sales in the most recent quarter.
These under-the-radar stocks could be poised to make big moves in the coming months.
Shareholder support for its proposed merger with Bristol-Myers appears back on track.